Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families.
Treatment of Chemotherapy-Induced Nausea in Cancer Patients report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market is projected to reach US$ 2123.1 million in 2029, increasing from US$ 2368.6 million in 2022, with the CAGR of -1.6% during the period of 2024 to 2029. Demand from Acute CINV and Delayed CINV are the major drivers for the industry.
The chemotherapy-induced nausea and vomiting (CINV) treatment market is driven by the increasing prevalence of cancer and the growing adoption of effective antiemetic therapies. Chemotherapy often causes nausea and vomiting, adversely affecting the quality of life of cancer patients. The rise in cancer incidence and the need for better supportive care contribute to market growth as healthcare providers and patients seek reliable CINV treatments to manage these distressing side effects. Moreover, advancements in antiemetic drug development and the introduction of combination therapies have improved treatment efficacy and patient outcomes. However, the market also faces challenges, including the individual variability in CINV response and the need for tailored treatment approaches. Additionally, addressing the cost of antiemetic drugs and ensuring accessibility to patients can pose obstacles for widespread adoption. To succeed, companies must focus on research and development to offer innovative and patient-centric CINV treatments, collaborate with oncologists to optimize treatment regimens, and address the challenges to meet the increasing demand for effective and well-tolerated antiemetic therapies for cancer patients undergoing chemotherapy.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Heron Therapeutics
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Roche
Mylan
Baxter
GSK
Helsinn
Southwest Pharma
Haisco
Sun Pharma
Segment by Type
5-HT3 Inhibitors
NK1 Inhibitors
Other
Acute CINV
Delayed CINV
Breakthrough CINV
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Treatment of Chemotherapy-Induced Nausea in Cancer Patients market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Treatment of Chemotherapy-Induced Nausea in Cancer Patients introduction, etc. Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Treatment of Chemotherapy-Induced Nausea in Cancer Patients market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Treatment of Chemotherapy-Induced Nausea in Cancer Patients report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market is projected to reach US$ 2123.1 million in 2029, increasing from US$ 2368.6 million in 2022, with the CAGR of -1.6% during the period of 2024 to 2029. Demand from Acute CINV and Delayed CINV are the major drivers for the industry.
The chemotherapy-induced nausea and vomiting (CINV) treatment market is driven by the increasing prevalence of cancer and the growing adoption of effective antiemetic therapies. Chemotherapy often causes nausea and vomiting, adversely affecting the quality of life of cancer patients. The rise in cancer incidence and the need for better supportive care contribute to market growth as healthcare providers and patients seek reliable CINV treatments to manage these distressing side effects. Moreover, advancements in antiemetic drug development and the introduction of combination therapies have improved treatment efficacy and patient outcomes. However, the market also faces challenges, including the individual variability in CINV response and the need for tailored treatment approaches. Additionally, addressing the cost of antiemetic drugs and ensuring accessibility to patients can pose obstacles for widespread adoption. To succeed, companies must focus on research and development to offer innovative and patient-centric CINV treatments, collaborate with oncologists to optimize treatment regimens, and address the challenges to meet the increasing demand for effective and well-tolerated antiemetic therapies for cancer patients undergoing chemotherapy.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Heron Therapeutics
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Roche
Mylan
Baxter
GSK
Helsinn
Southwest Pharma
Haisco
Sun Pharma
Segment by Type
5-HT3 Inhibitors
NK1 Inhibitors
Other
Segment by Application
Acute CINV
Delayed CINV
Breakthrough CINV
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Treatment of Chemotherapy-Induced Nausea in Cancer Patients market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Treatment of Chemotherapy-Induced Nausea in Cancer Patients introduction, etc. Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Treatment of Chemotherapy-Induced Nausea in Cancer Patients market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices